martes, 23 de junio de 2020

Breast Cancer Research | Articles

Breast Cancer Research | Articles



  1. An amendment to this paper has been published and can be accessed via the original article.
    Authors:Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato and Jenny C. Chang
    Citation:Breast Cancer Research 2020 22:52
    Content type:Correction
     
    Published on: 
    The original article was published in Breast Cancer Research 2020 22:4
  2. The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with ta...
    Authors:Swaathi Jayaraman, Xiaonan Hou, Mary J. Kuffel, Vera J. Suman, Tanya L. Hoskin, Kathryn E. Reinicke, David G. Monroe, Krishna R. Kalari, Xiaojia Tang, Megan A. Zeldenrust, Jingfei Cheng, Elizabeth S. Bruinsma, Sarah A. Buhrow, Renee M. McGovern, Stephanie L. Safgren, Chad A. Walden…
    Citation:Breast Cancer Research 2020 22:51
    Content type:Research article
     
    Published on: 
  3. Alterations in estrogen and progesterone signaling, via their respective receptors, estrogen receptor alpha (ERα) and progesterone receptor (PR), respectively, are largely involved in the development of breast...
    Authors:Henri-Philippe Konan, Loay Kassem, Soleilmane Omarjee, Ausra Surmieliova-Garnès, Julien Jacquemetton, Elodie Cascales, Amélie Rezza, Olivier Trédan, Isabelle Treilleux, Coralie Poulard and Muriel Le Romancer
    Citation:Breast Cancer Research 2020 22:50
    Content type:Research article
     
    Published on: 
  4. Most breast cancer-associated fibroblasts (CAFs) are active and important cancer-promoting cells, with significant impact on patient prognosis. Therefore, we investigated here the role of the protein kinase AT...
    Authors:Mysoon M. Al-Ansari, Maher Al-Saif, Maria Arafah, Abdelmonneim M. Eldali, Asma Tulbah, Taher Al-Tweigeri, Abdelhabib Semlali, Khalid S. Khabar and Abdelilah Aboussekhra
    Citation:Breast Cancer Research 2020 22:49
    Content type:Research article
     
    Published on: 
  5. The human epidermal growth factor receptor (HER) family, notably EGFR, is overexpressed in most triple-negative breast cancer (TNBC) cases and provides cancer cells with compensatory signals that greatly contr...
    Authors:Tejaswini P. Reddy, Dong S. Choi, Ann C. Anselme, Wei Qian, Wen Chen, Johan Lantto, Ivan D. Horak, Michael Kragh, Jenny C. Chang and Roberto R. Rosato
    Citation:Breast Cancer Research 2020 22:48
    Content type:Research article
     
    Published on: 
  6. The presence of tumor-infiltrating lymphocytes has been associated with prognosis and chemotherapy response, particularly in high-risk breast cancer subtypes. There is limited data so far as to (i) how tumor-i...
    Authors:Cornelia Kolberg-Liedtke, Gluz Oleg, Heinisch Fred, Feuerhake Friedrich, Kreipe Hans, Clemens Michael, Nuding Benno, Malter Wolfram, Reimer Toralf, Wuerstlein Rachel, Graeser Monika, Shak Steve, Nitz Ulrike, Kates Ronald, Christgen Matthias and Harbeck Nadia
    Citation:Breast Cancer Research 2020 22:47
    Content type:Research article
     
    Published on: 
  7. The presence of tumour-infiltrating lymphocytes (TILs) is associated with response to neoadjuvant chemotherapy among patients with triple-negative and HER2-positive breast cancer. However, the significance of ...
    Authors:Signe Korsgaard Skriver, Maj-Britt Jensen, Ann Soegaard Knoop, Bent Ejlertsen and Anne-Vibeke Laenkholm
    Citation:Breast Cancer Research 2020 22:46
    Content type:Research article
     
    Published on: 
  8. The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, i...
    Authors:Olga Martínez-Sáez, Nuria Chic, Tomás Pascual, Barbara Adamo, Maria Vidal, Blanca González-Farré, Esther Sanfeliu, Francesco Schettini, Benedetta Conte, Fara Brasó-Maristany, Adela Rodríguez, Débora Martínez, Patricia Galván, Ana Belén Rodríguez, Antonio Martinez, Montserrat Muñoz…
    Citation:Breast Cancer Research 2020 22:45
    Content type:Research article
     
    Published on: 
  9. Racial disparities in breast cancer survival between Black and White women persist across all stages of breast cancer. The metabolic syndrome (MetS) of insulin resistance disproportionately affects more Black ...
    Authors:Emily J. Gallagher, Kezhen Fei, Sheldon M. Feldman, Elisa Port, Neil B. Friedman, Susan K. Boolbol, Brigid Killelea, Melissa Pilewskie, Lydia Choi, Tari King, Anupma Nayak, Rebeca Franco, Daliz Cruz, Irini M. Antoniou, Derek LeRoith and Nina A. Bickell
    Citation:Breast Cancer Research 2020 22:40
    Content type:Research article
     
    Published on: 
  10. Early life environmental exposures affect breast development and breast cancer risk in adulthood. The breast is particularly vulnerable during puberty when mammary epithelial cells proliferate exponentially. I...
    Authors:Adam Burkholder, Dennis Akrobetu, Arun R. Pandiri, Kiki Ton, Sue Kim, Brian I. Labow, Laura C. Nuzzi, Joseph M. Firriolo, Sallie S. Schneider, Suzanne E. Fenton and Natalie D. Shaw
    Citation:Breast Cancer Research 2020 22:44
    Content type:Research article
     
    Published on: 
  11. Next-generation sequencing of Sri Lankan families with inherited cancer syndromes resulted in the identification of five BRCA2 variants of unknown clinical significance. Interpreting such variants poses significa...
    Authors:Nirmala Sirisena, Kajal Biswas, Teresa Sullivan, Stacey Stauffer, Linda Cleveland, Eileen Southon, Vajira H. W. Dissanayake and Shyam K. Sharan
    Citation:Breast Cancer Research 2020 22:43
    Content type:Short report
     
    Published on: 
  12. Stromal and collagen biology has a significant impact on tumorigenesis and metastasis. Collagen is a major structural extracellular matrix component in breast cancer, but its role in cancer progression is the ...
    Authors:Laurent Gole, Joe Yeong, Jeffrey Chun Tatt Lim, Kok Haur Ong, Hao Han, Aye Aye Thike, Yong Cheng Poh, Sidney Yee, Jabed Iqbal, Wanjin Hong, Bernett Lee, Weimiao Yu and Puay Hoon Tan
    Citation:Breast Cancer Research 2020 22:42
    Content type:Research article
     
    Published on: 
  13. In utero endocrine disruption is linked to increased risk of breast cancer later in life. Despite numerous studies establishing this linkage, the long-term molecular changes that predispose mammary cells to ca...
    Authors:Clarissa Wormsbaecher, Andrea R. Hindman, Alex Avendano, Marcos Cortes-Medina, Caitlin E. Jones, Andrew Bushman, Lotanna Onua, Claire E. Kovalchin, Alina R. Murphy, Hannah L. Helber, Ali Shapiro, Kyle Voytovitch, Xingyan Kuang, Renan Aguilar-Valenzuela, Jennifer L. Leight, Jonathan W. Song…
    Citation:Breast Cancer Research 2020 22:41
    Content type:Research article
     
    Published on: 
  14. Altered signaling pathways typify breast cancer and serve as direct inputs to steroid hormone receptor sensors. We previously reported that phospho-Ser134-GR (pS134-GR) species are elevated in triple-negative bre...
    Authors:Carlos Perez Kerkvliet, Amy R. Dwyer, Caroline H. Diep, Robert H. Oakley, Christopher Liddle, John A. Cidlowski and Carol A. Lange
    Citation:Breast Cancer Research 2020 22:39
    Content type:Research article
     
    Published on: 
  15. The highest incidence of breast cancer is in the Western world. Several aspects of the Western lifestyle are known risk factors for breast cancer. In particular, previous studies have shown that cholesterol le...
    Authors:Céline Ben Hassen, Jorge L. Gutierrez-Pajares, Cyrille Guimaraes, Roseline Guibon, Michelle Pinault, Gaëlle Fromont and Philippe G. Frank
    Citation:Breast Cancer Research 2020 22:38
    Content type:Research article
     
    Published on: 
  16. At least 50% of triple negative breast cancer (TNBC) overexpress the epidermal growth factor receptor, EGFR, which paved the way for clinical trials investigating its blockade. Outcomes remained dismal stemmin...
    Authors:Brooke N. McKnight, Seongho Kim, Julie L. Boerner and Nerissa T. Viola
    Citation:Breast Cancer Research 2020 22:37
    Content type:Research article
     
    Published on: 
  17. Multigene panels are routinely used to assess for predisposing germline mutations in families at high breast cancer risk. The number of variants of unknown significance thereby identified increases with the nu...
    Authors:Cédric Van Marcke, Raphaël Helaers, Anne De Leener, Ahmad Merhi, Céline A. Schoonjans, Jérôme Ambroise, Christine Galant, Paul Delrée, Françoise Rothé, Isabelle Bar, Elsa Khoury, Pascal Brouillard, Jean-Luc Canon, Peter Vuylsteke, Jean-Pascal Machiels, Martine Berlière…
    Citation:Breast Cancer Research 2020 22:36
    Content type:Research article
     
    Published on: 
  18. Osteoclast activation is a hallmark of breast cancer-induced bone disease while little is known about the role of osteoblasts in this process. Recently, we identified the homeodomain protein TG-interacting fac...
    Authors:Marie-Therese Haider, Hiroaki Saito, Jennifer Zarrer, Kevin Uzhunnumpuram, Sankari Nagarajan, Vijayalakshmi Kari, Michael Horn-Glander, Stefan Werner, Eric Hesse and Hanna Taipaleenmäki
    Citation:Breast Cancer Research 2020 22:34
    Content type:Research article
     
    Published on: 
  19. The PI3K/AKT/mTORC1 axis is implicated in hormone receptor-positive HER2-negative metastatic breast cancer (HR+ HER2− mBC) resistance to anti-estrogen treatments. Based on results of the BOLERO-2 trial, the mT...
    Authors:Claudio Vernieri, Francesca Corti, Federico Nichetti, Francesca Ligorio, Sara Manglaviti, Emma Zattarin, Carmen G. Rea, Giuseppe Capri, Giulia V. Bianchi and Filippo de Braud
    Citation:Breast Cancer Research 2020 22:33
    Content type:Review
     
    Published on: 
  20. The immune microenvironment in ductal carcinoma in situ (DCIS) and its significance are not well established. This study was conducted to evaluate the immune microenvironment of DCIS including the composition ...
    Authors:Milim Kim, Yul Ri Chung, Hyun Jeong Kim, Ji Won Woo, Soomin Ahn and So Yeon Park
    Citation:Breast Cancer Research 2020 22:32
    Content type:Research article
     
    Published on: 
  21. After publication of the original article [1], we were notified that the wrong version of Fig. 2b has been published
    Authors:Pankaj Chaudhary, Lee D. Gibbs, Sayantan Maji, Cheryl M. Lewis, Sumihiro Suzuki and Jamboor K. Vishwanatha
    Citation:Breast Cancer Research 2020 22:31
    Content type:Correction
     
    Published on: 
    The original article was published in Breast Cancer Research 2020 22:11
  22. Breast cancer is rare in men, but management is focused on tumor characteristics commonly found in female breast cancer. The tumor microenvironment of male breast cancer is less well understood, and insight ma...
    Authors:Si-Qi Qiu, Johan van Rooijen, Hilde H. Nienhuis, Bert van der Vegt, Hetty Timmer-Bosscha, Elise van Leeuwen-Stok, Annemiek M. E. Walenkamp, Carolien H. M. van Deurzen, Geertruida H. de Bock, Elisabeth G. E. de Vries and Carolien P. Schröder
    Citation:Breast Cancer Research 2020 22:30
    Content type:Research article
     
    Published on: 
  23. Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to r...
    Authors:Anup Tank, Hannah M. Peterson, Vivian Pera, Syeda Tabassum, Anais Leproux, Thomas O’Sullivan, Eric Jones, Howard Cabral, Naomi Ko, Rita S. Mehta, Bruce J. Tromberg and Darren Roblyer
    Citation:Breast Cancer Research 2020 22:29
    Content type:Research article
     
    Published on: 
  24. After the publication of the original article [1], we were notified the upper panel of the Fig. 1, where the patients’ codes are listed, was cropped by mistake so the patients 1–8 are repeated.
    Authors:Adi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, Amit Itay, Tal Sella, Moran Gadot, Karen Cesarkas, Sarit Farage-Barhom, Efrat Glick Saar, Eran Eyal, Nitzan Kol, Anya Pavlovski, Nora Balint-Lahat, Daniela Dick-Necula, Iris Barshack, Bella Kaufman…
    Citation:Breast Cancer Research 2020 22:28
    Content type:Correction
     
    Published on: 
    The original article was published in Breast Cancer Research 2020 22:16
  25. Palbociclib improves outcomes for women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC). Dose reductions are recommended for the manageme...
    Authors:Johannes Ettl, Seock-Ah Im, Jungsil Ro, Norikazu Masuda, Marco Colleoni, Patrick Schnell, Eustratios Bananis, Dongrui R. Lu, Massimo Cristofanilli, Hope S. Rugo and Richard S. Finn
    Citation:Breast Cancer Research 2020 22:27
    Content type:Research article
     
    Published on: 
  26. Breast cancer stem cells (BCSCs) are typically seed cells of breast tumor that initiate and maintain tumor growth. MiR-7, as a cancer inhibitor, decreases the BCSC subset and inhibits tumor progression through...
    Authors:Miao Li, Meng Pan, Chengzhong You, Fengshu Zhao, Di Wu, Mei Guo, Hui Xu, Fangfang Shi, Danfeng Zheng and Jun Dou
    Citation:Breast Cancer Research 2020 22:26
    Content type:Research article
     
    Published on: 
  27. After publication of the original article [1], we were notified that columns in Table 2 were erroneously displayed.
    Authors:Nasim Mavaddat, Antonis C. Antoniou, Thea M. Mooij, Maartje J. Hooning, Bernadette A. Heemskerk-Gerritsen, Catherine Noguès, Marion Gauthier-Villars, Olivier Caron, Paul Gesta, Pascal Pujol, Alain Lortholary, Daniel Barrowdale, Debra Frost, D. Gareth Evans, Louise Izatt, Julian Adlard…
    Citation:Breast Cancer Research 2020 22:25
    Content type:Correction
     
    Published on: 
    The original article was published in Breast Cancer Research 2020 22:8
  28. Experimental and epidemiological studies demonstrate a role for 27-hydroxycholesterol (27HC) in breast cancer development, though results are conflicting. Cholesterol 27-hydroxylase (CYP27A1) and oxysterol 7-a...
    Authors:Charlotte Le Cornet, Britta Walter, Disorn Sookthai, Theron S. Johnson, Tilman Kühn, Ester Herpel, Rudolf Kaaks and Renée T. Fortner
    Citation:Breast Cancer Research 2020 22:23
    Content type:Research article
     
    Published on: 
  29. In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine t...
    Authors:Christos Vaklavas, Brian S. Roberts, Katherine E. Varley, Nancy U. Lin, Minetta C. Liu, Hope S. Rugo, Shannon Puhalla, Rita Nanda, Anna Maria Storniolo, Lisa A. Carey, Mansoor N. Saleh, Yufeng Li, Jennifer F. Delossantos, William E. Grizzle, Albert F. LoBuglio, Richard M. Myers…
    Citation:Breast Cancer Research 2020 22:22
    Content type:Research article
     
    Published on: 
  30. Polygenic factors are estimated to account for an additional 18% of the familial relative risk of breast cancer, with those at the highest level of polygenic risk distribution having a least a twofold increase...
    Authors:Tatiane Yanes, Mary-Anne Young, Bettina Meiser and Paul A. James
    Citation:Breast Cancer Research 2020 22:21
    Content type:Review
     
    Published on: 
  31. As a consequence of responding to colleagues who asked about the publication of the original article [1], the authors have determined that the data published in Table 4 of the paper are incorrect.
    Authors:Danielle H. Bodicoat, Minouk J. Schoemaker, Michael E. Jones, Emily McFadden, James Griffin, Alan Ashworth and Anthony J. Swerdlow
    Citation:Breast Cancer Research 2020 22:19
    Content type:Correction
     
    Published on: 
    The original article was published in Breast Cancer Research 2014 16:R18

No hay comentarios:

Publicar un comentario